Table 9.
Sensitivity analysis
| Alternative | Added | Preserved | Overall | |||||
|---|---|---|---|---|---|---|---|---|
| Placebo | Candesartan | Placebo | Candesartan | Placebo | Candesartan | Placebo | Candesartan | |
| Increasing the length of stay for non-cardiovascular admissions by 30% | ||||||||
| Total | 10.03 (0.50) | 10.30 (0.45) | 11.26 (0.44) | 11.26 (0.39) | 7.77 (0.25) | 8.66 (0.25) | 9.53 (0.23) | 9.97 (0.20) |
| Adding one GP visit for an adverse event or laboratory abnormality | ||||||||
| Total | 10.03 (0.50) | 10.10 (0.44) | 11.26 (0.44) | 11.04 (0.39) | 7.77 (0.25) | 8.46 (0.25) | 9.53 (0.23) | 9.77 (0.20) |
| Sensitivity analysis 0% costs, 0% benefits | ||||||||
| Total | 10.33 (0.52) | 10.37 (0.70) | 11.65 (0.46) | 11.39 (0.40) | 7.98 (0.26) | 8.70 (0.26) | 9.82 (0.24) | 10.05 (0.21) |
| Sensitivity analysis 8% costs, 8% benefits | ||||||||
| Total | 9.56 (0.43) | 9.64 (0.48) | 10.63 (0.41) | 10.46 (0.37) | 7.42 (0.24) | 8.04 (0.24) | 9.06 (0.22) | 9.28 (0.19) |